Published: Jan 15, 2021
LOS ANGELES (BUSINESS WIRE) CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) and ImmunityBio, Inc. (“ImmunityBio”) have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer have produced early indications of increased survival rates for patients with no other approved treatment options. Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer (for which no other FDA approved treatment exists).
Search jobs NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options
In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor) completed in 2019, median overall survival rate more than doubled compared to historical controls (eight months versus three months)
A complete remission was achieved when replacing haNK and PD-L1 checkpoint inhibitor avelumab with PD-L1 t-haNK and four out of five patients are alive 8-16 months since beginning treatment on these expanded protocols
Press release content from Business Wire. The AP news staff was not involved in its creation.
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
January 13, 2021 GMT
EL SEGUNDO & CULVER CITY, Calif. (BUSINESS WIRE) Jan 13, 2021
NantKwest, Inc. ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immunotherapy company, today announced early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists. These trials, which were based on the original Cancer Moonshot hypothesis and exploratory QUILT trials initiated in 2017, appear to validate the theory that by orchestrating natural killer and T-cell therapy, survival rates could be improved without high-dose chemotherapy.
Photo: WNAX
Covid-19 vaccinations are going at a rapid pace in South Dakota with health care and long-term care providers in the first round.
Dr David Basel, Medical Director at Avera McKennan Hospital in Sioux Falls says they have a lot of their people vaccinated…
Basel says Covid-19 related hospitalization have dropped…
Basel says they are watching for signs of the Covid-19 virus mutation…
Basel says it is still important for people to wear masks, socially distance and wash hands to hold down infection spread. Tags:
Recent Headlines
One of the most important blood drives of the year is now underway here in the Sioux Empire.
The 25th annual “Heroes Behind the Badges” blood drive kicked off on Monday (December 28) and will continue each day through (January 8).
The Heroes Behind the Badges blood drive is a friendly little competition between the Sioux Falls Police and Firefighters to see which team can get the most blood donations.
As Dakota News Now reports all the donations made throughout the drive will stay right here to help residents in the Sioux Empire.
One big change was made to this year s blood drive due to the pandemic, those wishing to make a blood donation must first schedule an appointment to give blood.